Evidence map›Paper›PMID 16757425›Full record

ReviewInternational journal of hematology2006

New therapeutic approach for myeloid leukemia: induction of apoptosis via modulation of reactive oxygen species production by natural compounds.

Masahiro Kizaki

Abstract readReview
PubMed Publisher
In one paragraph

Review in International journal of hematology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Masahiro KizakiDivision of Hematology, Keio University School of Medicine, Tokyo, Japan. makizaki@sc.itc.keio.ac.jp
Keio University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The therapeutic approach to acute myeloid leukemia is based on chemotherapy, but the side effects of the drugs used and various complications, including infections and bleedings, are sometimes fatal. Recently, imatinib mesylate has shown remarkable efficacy and less toxicity as a molecularly targeted therapy in patients with chronic myeloid leukemia. Natural products appear to be safer than the current chemotherapeutic drugs, and we have therefore sought out new potential agents from various natural compounds with the ability to induce the apoptosis of myeloid leukemic cells.

Indexed as

AnimalsAntineoplastic Agents, PhytogenicApoptosisBenzamidesHemorrhageHumansImatinib MesylateInfectionsLeukemia, Myeloid, AcutePiperazinesPyrimidinesReactive Oxygen SpeciesAntineoplastic Agents, PhytogenicBenzamidesImatinib MesylatePiperazinesPyrimidinesReactive Oxygen Species

Identifiers

PMID16757425
OpenAlexW1997696701

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.